Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1994-01-19
1995-10-24
Jordan, Kimberly R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514182, 514843, A61K 3156
Patent
active
054610419
ABSTRACT:
Disclosed is an oral contraceptive regimen containing daily dosage units each containing from 70 to 80 micrograms of desogestrel, 3-ketodesogestrel or mixtures thereof. It has been found that by making a selection of desogestrel or 3-ketodesogestrel at the described dosages in an oral contraceptive regimen administered over the entire menstrual cycle (e.g. 28 days), effective ovulation inhibition is achieved and intermenstrual bleeding is avoided, while acceptable cycle control is retained. Moreover, the regimen also prevents the formation of persistent ovarian cysts.
REFERENCES:
patent: 4066757 (1978-01-01), Pasquale
patent: 4957119 (1990-09-01), de Nijs
patent: 5088505 (1992-02-01), de Nijs
patent: 5150718 (1992-09-01), de Nijs
CA 111(19):168149q, De Nijs, 1989.
S. E. Olsson et al., "Clinical Results with Subcutaneous implant containing 3-keto Desogestrel", pp. 1-11, published Jul., 1990, Contraception 42(1) published in England.
H. Helwig et al., "Helwig Arzneimittel, ein Handbuch fur Arzte und Apotheker", chapter 29-51, 6th Edition, 1988, Germany.
Odlind and Fraser, "Contraception and menstrual bleeding disturbances: A Clinical overview," Contraception and Mechanisms of endometrail bleeding, WHO, pp. 5-32, Cambridge University Press, 1990.
Mintz et al., "Contraception with Progestagens in Systemic Lupus Erythematosus," Contraception, 30:29-38, 1984.
Tayob et al., "Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception," British Journal of Obstetrics and Gynaecology, 92:1003-1009, 1985.
Tezabwala et al., "Studies on cell-mediated Immunity in Women Using Different Fertility Regulating Methods," J. Clin. Lab Immunol., 10:199-202 (1983).
E. M. Belsey, "Vaginal Bleeding Patterns Among Women Using One Natural and Eight Hormonal Methods of Contraception," Contraception, 38(2):181-206 (1988).
Bisset et al., "The efficacy of the progestogen-only pill as a contraceptive method," The British Journal of Family Planning, 16:84-87 (1990).
Landgren and Diczfalusy, "Hormonal Effects of the 300ug Norethisterone Minipill," Contraception, 21(1):87-113 (1980).
Bennink Herman J. T. C.
Bergink Engelbert W.
Akzo Nobel N.V.
Gormley Mary E.
Jordan Kimberly R.
LandOfFree
Progestogen-only contraceptive does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Progestogen-only contraceptive, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Progestogen-only contraceptive will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1886739